Genentech Executive Vice President Richard Scheller describes the hard financial realities of producing cutting-edge drugs for the developed world. Scheller states that it takes 15 years, on average, for a drug product to move from concept to sale. This fact, along with the company’s large-scale financial investments, places tremendous pricing pressure on the finished product.
